NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma
- Genentech, United States
Figures
Figure 1
TP63 regulates NRG1 in SCC.
(A) Correlation of TP63 and NRG1 in LUSC (n = 223) and Esophageal (n = 263) patient samples in TCGA data set. Statistical significance was determined by two-tailed test and Pearson correlation (r) …
Figure 2
Modest but significant growth inhibition of SCCs by anti-NRG1 treatment in vitro.
(A) NRG1 and ERBB3 mRNA levels in head and neck squamous carcinoma (HNSC), lung squamous carcinoma (LUSC) and lung adenocarcinoma (LUAD) patient samples from TCGA. (B) In vitro growth of different …
Figure 3 with 2 supplements
Anti-NRG1 significantly inhibits the tumor growth in vivo of SCCs that express both NRG1 and ERBB3.
Effect of anti-NRG1 or anti-Ragweed (control) antibodies in (A) FaDu (head and neck), HCC95 (lung) and KYSE-180 (esophagus) SCC cell lines in preclinical mouse xenograft models, N = 8–12 mice/group, …
Figure 3—figure supplement 1
Anti-NRG1 inhibits in vivo tumor growth in SCC models.
Effect of anti-NRG1 or anti-Ragweed (control) antibodies in FaDu (head and neck), HCC95 (lung) and KYSE-180 (esophagus) SCC cell lines in preclinical mouse xenograft models, N = 8–12 mice/group. …
Figure 3—figure supplement 2
Anti-NRG1 does not inhibit the growth of ovarian models expressing NRG1 and ERBB3 receptor in vivo.
(A) In vitro growth of ovarian cell lines in the presence of anti-NRG1 or anti-Ragweed (control) antibody. Expression of NRG1, Erbb3, Erbb4 and TP63 by RNAseq are shown below the respective in vitro …
Figure 4 with 3 supplements
Anti-NRG1 induces squamous differentiation and inhibits proliferation in SCCs.
(A) Representative image of KRT10 (differentiation marker) staining of tumor from FaDu and HCC95 SCC models upon anti-NRG1 treatments compared to anti-Ragweed control. N = 5 mice/group. (B) Protein …
-
Figure 4—source data 1
Panel of human airway basal cell gene signature in Figure 4C (as published by Hackett et al., 2011).
- https://doi.org/10.7554/eLife.46551.011
Figure 4—figure supplement 1
Anti-NRG1 induces differentiation in SCC.
Representative image of H and E staining of KYSE-180, HCC95 and FaDu tumors upon anti-NRG1 treatments compared to anti-Ragweed control. N = 5 mice/group.
Figure 4—figure supplement 2
Anti-NRG1 inhibits proliferation and induces differentiation in SCC.
Expression of proliferation, differentiation and progenitor cell related markers following one dose of anti-NRG1 relative to anti-Ragweed treatment in HCC95 lung SCC xenograft tumors by RNAseq. …
Figure 4—figure supplement 3
Anti-NRG1 increases differentiation markers in vitro in SCC.
Relative expression of differentiation markers such as KRT1, KRT10, IVL and KRTDAP in FaDu, HCC95 and KYSE-180 cell lines after treatment with antibodies for 3 days in vitro.
Tables
Key resources table
| Reagent type (species)or resource | Designation | Source or reference | Identifiers | Additional information |
|---|---|---|---|---|
| Strain, strainbackground (M. musculus) | C.B-17 SCID beige mice | Charles River Labs | CB17.Cg-PrkdcscidLystbg-J/Crl | |
| Strain, strainbackground (M. musculus) | Athymic nude mice | Harlan Sprague Dawley (Livermore facility) | Hsd:Athymic Nude-Foxn1nu | |
| Genetic reagent (M. musculus) | Lgr5CreERT2+; tdTomato; KrasG12Dwt/ki; PTENloxP/loxP | Lgr5CreERT2+; pubmed id:21927002 tdTomato; pubmed id: PMC2840225 KrasG12Dwt/ki; pubmed id: 11751630 PTENloxP/loxP; pubmed id: 11691952 | LAR, Genentech | |
| Antibody | Anti-Ragweed | Genentech | 9652 | In vivo: 20 mg/kg, i.p.,qwk In vitro: 20 ug/ml |
| Antibody | Anti-NRG1 | Genentech | YW538.24.71 | In vivo: 20 mg/kg, i.p.,qwk In vitro: 20 ug/ml |
| Antibody | deltaNTP63 (Rabbit Polyclonal IgG) | Biolegend | RRID:AB_2256361 Cat. #: 619001 | WB (1:1000) |
| Antibody | Actin (Mouse IgG) | BD Bioscience | RRID:AB_2289199 Cat. #: 612656 | WB (1:5000) |
| Antibody | p-ERBB3 (Rabbit mAb) | Cell Signaling Technologies | RRID:AB_2099709 Cat. #: 4791 | WB (1:500) |
| Antibody | ERBB3 (Rabbit mAb) | Cell Signaling Technologies | RRID:AB_2721919 Cat. #: 12708 | WB (1:500) |
| Antibody | Rabbit PARP (Rabbit polyclonal) | Cell Signaling Technologies | RRID:AB_2160739 Cat. #: 9542 | WB (1:1000) |
| Antibody | Cleaved caspase-3 (Rabbit mAb) | Cell Signaling Technologies | Cat. #: 9664 | WB (1:1000) |
| Antibody | TP63 alpha (Rabbit mAb) | Cell Signaling Technologies | RRID:AB_2637091 Cat. #: 13109 | CHIP (1:100) WB (1:1000) |
| Antibody | KRT10 (Rabbit polyclonal) | Covance Biologicals | RRID:AB_291580 Cat. #: PRB-159P | IHC (1:1000) |
| Commercial assay or kit | TP63-all | Life Technologies | Hs00978340_m1 | qPCR |
| Commercial assay or kit | TA-TP63-TA | Life Technologies | Hs00186613_m1 | qPCR |
| Commercial assay or kit | deltaN-TP63 | Life Technologies | Hs00978339_m1 | qPCR |
| Commercial assay or kit | NRG1a | Life Technologies | Hs01103794_m1 | qPCR |
| Commercial assay or kit | NRG1b | Life Technologies | Hs00247624_m1 | qPCR |
| Commercial assay or kit | KRTDAP | Life Technologies | Hs00415563_m1 | qPCR |
| Commercial assay or kit | KRT1 | Life Technologies | Hs00196158_m1 | qPCR |
| Commercial assay or kit | KRT10 | Life Technologies | Hs00166289_m1 | qPCR |
| Commercial assay or kit | IVL | Life Technologies | Hs00846307_s1 | qPCR |
| Other | TA-TP63 | Dharmacon | #13 = J-003330–13 | siRNA |
| Other | all isoform-TP63 | Dharmacon | #14 = J-003330–14 | siRNA |
| Other | NTC#3 | Dharmacon | D-001810–03 | siRNA |
| Other | NTC#4 | Dharmacon | D-001810–04 | siRNA |
| Software,algorithm | GraphPad Prism | graphpad.com | RRID:SCR_002798 |
Additional files
-
Transparent reporting form
- https://doi.org/10.7554/eLife.46551.012
